VIR
Closed
Vir Biotechnology Inc
7.72
-0.15 (-1.91%)
Last Update: 17 Oct 2024 23:00:00
Yesterday: 7.87
Day's Range: 7.7 - 7.8999
Send
sign up or login to leave a comment!
When Written:
23.51
Vir Biotechnology Inc is a clinical-stage immunology company that develops therapies for infectious diseases. The company's focus is on developing treatments for serious viral infections, including COVID-19, hepatitis B, influenza, and HIV.
Vir Biotechnology was founded in 2016 by George Scangos, the former CEO of Biogen, and a team of experienced biotech executives. The company is headquartered in San Francisco, California, and has research facilities in Cambridge, Massachusetts, and Durham, North Carolina.
Vir Biotechnology's approach to developing therapies involves identifying and targeting specific viral proteins that are essential for the virus to replicate and spread. The company uses a combination of computational biology, antibody engineering, and drug discovery to develop treatments that can block these viral proteins and prevent infection.
In response to the COVID-19 pandemic, Vir Biotechnology has developed an antibody therapy called VIR-7831, which has shown promising results in early-stage clinical trials. The company is also working on developing a vaccine for COVID-19 in collaboration with GlaxoSmithKline.
Vir Biotechnology has partnerships with several other pharmaceutical companies, including Alnylam Pharmaceuticals, Biogen, and GSK. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol VIR.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vir Biotechnology was founded in 2016 by George Scangos, the former CEO of Biogen, and a team of experienced biotech executives. The company is headquartered in San Francisco, California, and has research facilities in Cambridge, Massachusetts, and Durham, North Carolina.
Vir Biotechnology's approach to developing therapies involves identifying and targeting specific viral proteins that are essential for the virus to replicate and spread. The company uses a combination of computational biology, antibody engineering, and drug discovery to develop treatments that can block these viral proteins and prevent infection.
In response to the COVID-19 pandemic, Vir Biotechnology has developed an antibody therapy called VIR-7831, which has shown promising results in early-stage clinical trials. The company is also working on developing a vaccine for COVID-19 in collaboration with GlaxoSmithKline.
Vir Biotechnology has partnerships with several other pharmaceutical companies, including Alnylam Pharmaceuticals, Biogen, and GSK. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol VIR.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!